blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2397155

EP2397155 - Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway [Right-click to bookmark this link]
Former [2011/51]Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
[2017/28]
StatusPatent revoked
Status updated on  08.03.2024
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  10.11.2017
FormerGrant of patent is intended
Status updated on  28.06.2017
FormerExamination is in progress
Status updated on  01.11.2016
Most recent event   Tooltip08.03.2024Revocation of patentpublished on 10.04.2024  [2024/15]
Applicant(s)For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215 / US
For all designated states
The Brigham and Women's Hospital, Inc.
75 Francis Street
Boston, MA 02115 / US
For all designated states
Emory University
1599 Clifton Road NE
4th Floor
Atlanta, GA 30322 / US
For all designated states
President and Fellows of Harvard College
17 Quincy Street
Cambridge, MA 02138 / US
[2017/28]
Former [2013/45]For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215 / US
For all designated states
The Brigham and Women's Hospital, Inc.
1249 Boyleston street, Suite 201
Boston, Massachusetts 02215 / US
For all designated states
Emory University
201 Dowman Drive 101 Administration Bldg.
Atlanta, GA 30322-1018 / US
For all designated states
President and Fellows of Harvard College
17 Quincy Street
Cambridge, MA 02138 / US
Former [2011/51]For all designated states
Dana Farber Cancer Institute
44 Binney Street - Jimmy Fund Building
Boston, MA 02115 / US
For all designated states
The Brigham and Women's Hospital, Inc.
1249 Boyleston street, Suite 201
Boston, Massachusetts 02215 / US
For all designated states
Emory University
201 Dowman Drive 101 Administration Bldg.
Atlanta, GA 30322-1018 / US
For all designated states
The President and Fellows of Harvard College
17 Quincy Street
Cambridge MA 02138-3805 / US
Inventor(s)01 / Freeman, Gordan
305 Walnut Street
Brookline, MA 02445 / US
02 / Sharpe, Arlene
305 Walnut Street
Brookline, MA 02445 / US
03 / Dorfman, David M.
42 Welland Road
Brookline, MA 02445 / US
04 / Ahmed, Rafi
1811 Durand Mill Drive
Atlanta, GA 30307 / US
05 / Barber, Daniel
5440 Marinelli Road, Apt. 206
North Bethesda, MD 20852 / US
06 / Wherry, E. John
110 Myrtie Avenue
Havertown, Pennsylvania 19083 / US
 [2011/51]
Representative(s)Forresters IP LLP
Skygarden
Erika-Mann-Straße 11
80636 München / DE
[N/P]
Former [2017/50]Donald, Jenny Susan, et al
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2012/13]Gowshall, Jonathan Vallance, et al
Forrester & Boehmert
SkyGarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2011/51]Gowshall, Jonathan Vallance
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date11162667.708.06.2006
[2011/51]
Priority number, dateUS20050688872P08.06.2005         Original published format: US 688872 P
[2011/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2397155
Date:21.12.2011
Language:EN
[2011/51]
Type: B1 Patent specification 
No.:EP2397155
Date:13.12.2017
Language:EN
[2017/50]
Search report(s)(Supplementary) European search report - dispatched on:EP18.11.2011
ClassificationIPC:A61K39/00, A61P31/12, A61P31/18, A61P31/22, G01N33/53, // C07K16/28
[2017/28]
CPC:
A61K31/713 (EP,IL,US); C07K16/2803 (IL,US); A61K39/395 (KR,RU);
A61K38/1709 (EP,IL,US); A61K39/39 (EP,IL,US); A61K39/3955 (US);
A61K39/39558 (US); A61K45/06 (EP,IL,US); A61P1/16 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P31/06 (EP);
A61P31/10 (EP); A61P31/12 (EP); A61P31/14 (EP);
A61P31/18 (EP); A61P31/20 (EP); A61P31/22 (EP);
A61P33/00 (EP); A61P33/02 (EP); A61P33/06 (EP);
A61P35/00 (EP,RU); A61P37/04 (EP); A61P43/00 (EP);
C07K16/28 (KR); C07K16/2818 (EP,IL,US); C07K16/2827 (EP,IL,US);
C12N15/1138 (US); G01N33/5011 (EP,IL,US); G01N33/505 (EP,IL,US);
G01N33/53 (KR); G01N33/57484 (EP,IL,US); G01N33/57492 (EP,IL,US);
A61K2039/505 (EP,IL,US); A61K2039/507 (US); A61K2039/55516 (EP,IL,US);
A61K2039/55566 (EP,IL,US); A61K2039/572 (EP,IL,US); C07K2317/70 (EP,IL,US);
C07K2317/73 (US); C07K2317/74 (EP,IL,US); C07K2317/76 (EP,IL,US);
C12N2310/14 (US); G01N2800/26 (EP,IL,US); Y02A50/30 (US) (-)
Former IPC [2011/51]A61K39/395, G01N33/53, // C07K16/28
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/50]
Former [2011/51]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Verfahren und Zusammensetzungen zur Behandlung persistenter Infektionen mittels Hemmung des programmierten 1 (PD-1)-Zelltodweges[2017/28]
English:Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway[2017/28]
French:Procédés et compositions pour le traitement d'infections persistantes en inhibant la voie de la mort cellulaire programmée (PD-1)[2017/28]
Former [2011/51]Verfahren und Zusammensetzungen zur Behandlung persistenter Infektionen und Krebs mittels Hemmung des programmierten 1 (pd-1)-Zelltodweges
Former [2011/51]Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
Former [2011/51]Procédés et compositions pour le traitement du cancer et d'infections persistantes en inhibant la voie de la mort cellulaire programmée (pd-1)
Examination procedure21.06.2012Amendment by applicant (claims and/or description)
21.06.2012Examination requested  [2012/31]
06.03.2013Despatch of a communication from the examining division (Time limit: M06)
30.08.2013Reply to a communication from the examining division
06.09.2013Observations by third parties
16.09.2013Despatch of a communication from the examining division (Time limit: M02)
26.09.2013Reply to a communication from the examining division
07.11.2014Despatch of a communication from the examining division (Time limit: M04)
11.03.2015Reply to a communication from the examining division
22.06.2015Despatch of a communication from the examining division (Time limit: M04)
22.10.2015Reply to a communication from the examining division
11.03.2016Despatch of a communication from the examining division (Time limit: M04)
15.07.2016Reply to a communication from the examining division
21.10.2016Despatch of a communication from the examining division (Time limit: M04)
23.01.2017Reply to a communication from the examining division
05.07.2017Communication of intention to grant the patent
01.11.2017Fee for grant paid
01.11.2017Fee for publishing/printing paid
01.11.2017Receipt of the translation of the claim(s)
22.11.2017Request for correction of the decision to grant filed
Parent application(s)   TooltipEP06784684.0  / EP1907000
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060784684) is  15.04.2009
Opposition(s)Opponent(s)01  11.09.2018  14.09.2018  ADMISSIBLE
Sanofi
54 Rue La Boétie
75008 Paris / FR
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 02  12.09.2018  17.09.2018  ADMISSIBLE
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591 / US
Opponent's representative
J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
 03  13.09.2018  18.09.2018  ADMISSIBLE
Janssen Sciences Ireland UC
Eastgate Village
Eastgate
Little Island
Cork / IE
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 [N/P]
Former [2021/37]
Opponent(s)01  11.09.2018  14.09.2018  ADMISSIBLE
Sanofi
54 Rue La Boétie
75008 Paris / FR
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 02  12.09.2018  17.09.2018  ADMISSIBLE
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591 / US
Opponent's representative
J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 03  13.09.2018  18.09.2018  ADMISSIBLE
Janssen Sciences Ireland UC
Eastgate Village
Eastgate
Little Island
Cork / IE
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Former [2018/43]
Opponent(s)01  11.09.2018  14.09.2018  ADMISSIBLE
Sanofi
54 Rue La Boétie
75008 Paris / FR
Opponent's representative
Holland, David Christopher
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 02  12.09.2018  17.09.2018  ADMISSIBLE
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591 / US
Opponent's representative
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 03  13.09.2018  18.09.2018  ADMISSIBLE
Janssen Sciences Ireland UC
Eastgate Village
Eastgate
Little Island
Cork / IE
Opponent's representative
Wise, Daniel Joseph
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Former [2018/42]
Opponent(s)01  11.09.2018    ADMISSIBLE
Sanofi
54 Rue La Boétie
75008 Paris / FR
Opponent's representative
Holland, David Christopher
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 02  12.09.2018    ADMISSIBLE
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown NY 10591 / US
Opponent's representative
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
27.09.2018Invitation to proprietor to file observations on the notice of opposition
07.02.2019Reply of patent proprietor to notice(s) of opposition
09.12.2019Date of oral proceedings
20.01.2020Despatch of minutes of oral proceedings
20.01.2020Despatch of communication that the patent will be revoked
18.10.2023Legal effect of revocation of patent [2024/15]
Appeal following opposition19.03.2020Appeal received No.  T0737/20
02.06.2020Statement of grounds filed
18.10.2023Result of appeal procedure: appeal of the proprietor was rejected
07.03.2024Despatch of the decision of the Board of Appeal
18.10.2023Date of oral proceedings
Fees paidRenewal fee
15.04.2011Renewal fee patent year 03
15.04.2011Renewal fee patent year 04
18.04.2011Renewal fee patent year 05
13.06.2011Renewal fee patent year 06
14.06.2012Renewal fee patent year 07
10.06.2013Renewal fee patent year 08
31.03.2014Renewal fee patent year 09
10.06.2015Renewal fee patent year 10
10.06.2016Renewal fee patent year 11
16.06.2017Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.06.2006
AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
PT13.12.2017
RO13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
TR13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
IE08.06.2018
LU08.06.2018
BE30.06.2018
[2020/27]
Former [2020/16]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
TR13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
IE08.06.2018
LU08.06.2018
BE30.06.2018
Former [2019/24]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
IE08.06.2018
LU08.06.2018
BE30.06.2018
Former [2019/19]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
IE08.06.2018
LU08.06.2018
Former [2019/17]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
LU08.06.2018
Former [2019/15]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
MC13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
Former [2019/13]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SI13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/51]AT13.12.2017
CY13.12.2017
CZ13.12.2017
DK13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/40]AT13.12.2017
CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
RO13.12.2017
SE13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/39]AT13.12.2017
CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
IT13.12.2017
LT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
SE13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/38]AT13.12.2017
CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
LT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
SE13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
IS13.04.2018
Former [2018/37]CY13.12.2017
CZ13.12.2017
EE13.12.2017
ES13.12.2017
FI13.12.2017
LT13.12.2017
LV13.12.2017
NL13.12.2017
PL13.12.2017
SE13.12.2017
SK13.12.2017
BG13.03.2018
GR14.03.2018
Former [2018/34]FI13.12.2017
LT13.12.2017
LV13.12.2017
NL13.12.2017
SE13.12.2017
BG13.03.2018
GR14.03.2018
Former [2018/24]FI13.12.2017
LT13.12.2017
LV13.12.2017
SE13.12.2017
BG13.03.2018
GR14.03.2018
Former [2018/23]FI13.12.2017
LT13.12.2017
SE13.12.2017
GR14.03.2018
Former [2018/22]FI13.12.2017
LT13.12.2017
Documents cited:Search[A]WO0200730  (GENETICS INST [US], et al) [A] 1 * page 107 *;
 [XY]WO2004004771  (ONO PHARMACEUTICAL CO [JP], et al) [X] 1,4-8,10-17 * the whole document * [Y] 2,3;
 [A]WO2004056875  (WYETH CORP [US], et al) [A] 1 * paragraph [0042] *;
 EP1537878  [ ] (ONO PHARMACEUTICAL CO [JP], et al) [ ] * paragraph [0035] * * paragraph [0037] * * paragraph [0055] * * paragraph [0057] * * paragraph [0051] *;
 [Y]  - TRABATTONI DARIA ET AL, "B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.", BLOOD 1 APR 2003, (20030401), vol. 101, no. 7, ISSN 0006-4971, pages 2514 - 2520, XP002419628 [Y] 2,3 * page 2516 *

DOI:   http://dx.doi.org/10.1182/blood-2002-10-3065
 [X]  - HIRANO FUMIYA ET AL, "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.", CANCER RESEARCH 1 FEB 2005, (20050201), vol. 65, no. 3, ISSN 0008-5472, pages 1089 - 1096, XP002419626 [X] 1 * page 1091, column R *
 [A]  - IWAI YOSHIKO ET AL, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (20020917), vol. 99, no. 19, ISSN 0027-8424, pages 12293 - 12297, XP002398159 [A] 1 * page 12295 *

DOI:   http://dx.doi.org/10.1073/pnas.192461099
 [AP]  - BARBER DANIEL L ET AL, "Restoring function in exhausted CD8 T cells during chronic viral infection.", NATURE 9 FEB 2006, (20060209), vol. 439, no. 7077, ISSN 1476-4687, pages 682 - 687, XP002419629 [AP] 1-17 * the whole document *

DOI:   http://dx.doi.org/10.1038/nature04444
 [AP]  - HE LANXIANG ET AL, "Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma.", ANTICANCER RESEARCH 2005 SEP-OCT, (200509), vol. 25, no. 5, ISSN 0250-7005, pages 3309 - 3313, XP009078741 [AP] 1 * abstract *
 [A]  - BLANK CHRISTIAN ET AL, "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII APR 2005, (200504), vol. 54, no. 4, ISSN 0340-7004, pages 307 - 314, XP002419627 [A] 1 * figure 2 *

DOI:   http://dx.doi.org/10.1007/s00262-004-0593-x
 [A]  - OHIGASHI YUICHIRO ET AL, "Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 APR 2005, (20050415), vol. 11, no. 8, ISSN 1078-0432, pages 2947 - 2953, XP002419631 [A] 1 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-04-1469
by applicantUS3625214
 US4230767
 US4233402
 US4275149
 US4376110
 US4659678
 US4727022
 US4789734
 WO8907136
 US4925673
 US5698520
 US5954687
 US6368832
 US2002107363
 US2002106730
 US2002110836
 US2002160000
 US2002164600
 US2003039653
 US2003044768
 US2003064380
 US6579854
 US2003166531
 US2003232323
 US2004137577
 US6808710
    - ISHIDA ET AL., EMBO J., (1992), vol. 11, pages 3887 - 3895
    - SHINOHARA ET AL., GENOMICS, (1994), vol. 23, pages 704 - 706
    - KANG ET AL., SCIENCE, (1992), vol. 257, page 1134
    - BERZOFSKY ET AL., J. CLIN. INVEST., (2004), vol. 114, pages 456 - 462
    - JOLIOT ET AL., PROC NATL ACAD SCI USA, (1991), vol. 88, pages 1864 - 1868
    - ROSENBERG ET AL., N. ENG. J. MED., (1990), vol. 323, no. 9, pages 570 - 578
    - KOTIN ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 2211 - 2215
    - LU ET AL., Abstracts of the Meeting on Gene Therapy, COLD SPRING HARBOR LABORATORY, page 66
    - GREGORIADIS, Drug Carriers in Biology and Medicine, ACADEMIC PRESS, (1979), pages 287 - 341
    - DONG ET AL., NATURE, (1999), vol. 5, pages 1365 - 1369
    - O'MARCAIGH AS, JACOBSON RM, "Estimating The Predictive Value Of A Diagnostic Test, How To Prevent Misleading Or Confusing Results", CLIN. PED., (1993), vol. 32, no. 8, pages 485 - 491
    - "Clinical Interpretation Of Laboratory Procedures", SHULTZ, Fundamentals of Clinical Chemistry, W.B. SAUNDERS COMPANY, (1996), pages 192 - 199
    - ZWEIG ET AL., "ROC Curve Analysis: An Example Showing The Relationships Among Serum Lipid And Apolipoprotein Concentrations In Identifying Patients With Coronory Artery Disease", CLIN. CHEM., (1992), vol. 38, no. 8, pages 1425 - 1428
    - KAECH ET AL., CELL, (2002), vol. 111, pages 837 - 51
    - AHMED ET AL., J. VIROL., (1984), vol. 51, pages 34 - 41
    - WHERRY ET AL., J. VIROL., (2003), vol. 77, pages 4911 - 27
otherWO2004004771
OppositionWO0114557
 WO0200730
 WO02079499
 WO02086083
 WO2004004771
 WO2007005874
 US2007122378
    - IWAI et al., "PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver", J. Exp. Med., (20030000), vol. 198, no. 1, pages 39 - 50, XP055011230

DOI:   http://dx.doi.org/10.1084/jem.20022235
    - TRABATTONI et al., "B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression", Blood, (20030000), vol. 101, no. 7, pages 2514 - 20, XP002419628

DOI:   http://dx.doi.org/10.1182/blood-2002-10-3065
    - BARBER et al., "Restoring function in exhausted CD8 T cells during chronic viral infection", Nature, (20060000), vol. 439, no. 7077, pages 682 - 687, XP002419629

DOI:   http://dx.doi.org/10.1038/nature04444
    - ISOGAWA et al., "Oscillating CDS+ T Cell Effector Functions after Antigen Recognition in the Liver", Immunity, (20050000), vol. 23, no. 1, pages 53 - 63, XP055519557
    - KIRCHBERGER et al., "Human Rhinoviruses Inhibit the Accessory Function of Dendritic Cells by Inducing Sialoadhesin and B7-Hl Expression1", J. Immunol., (20050000), vol. 175, no. 2, pages 1145 - 1152, XP055519558
    - OKAZAKI et al., "The PD-1-PD-L pathway in immunological tolerance", Trends in Immunology, (20060000), vol. 27, no. 4, pages 195 - 201, XP005365361

DOI:   http://dx.doi.org/10.1016/j.it.2006.02.001
    - CARUNTU et al., "CccDNA Persistence during Natural Evolution of Chronic VHB Infection", Romanian J. Gastroenterology, (20051200), vol. 14, no. 4, pages 373 - 377, XP055519560
    - JEON et al., "PD-L1/B-7-H1 regulates the survival but not the function of CD8+ T cells in HSV-1 latently infected trigeminal ganglia", J. Immunol., (20130000), vol. 190, no. 12, pages 6277 - 6286, XP055519561

DOI:   http://dx.doi.org/10.4049/jimmunol.1300582
    - NAKAMOTO et al., "Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization", Gastroenterology, (20080000), vol. 134, no. 7, pages 1927 - 1937, XP022694434

DOI:   http://dx.doi.org/10.1053/j.gastro.2008.02.033
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.